Uenaka T - Search Results

1

Pladienolides, new substances from culture of Streptomyces platensis Mer-11107. III. In vitro and in vivo antitumor activities.

Mizui Y, Sakai T, Iwata M, Uenaka T, Okamoto K, Shimizu H, Yamori T, Yoshimatsu K, Asada M. Mizui Y, et al. Among authors: uenaka t. J Antibiot (Tokyo). 2004 Mar;57(3):188-96. doi: 10.7164/antibiotics.57.188. J Antibiot (Tokyo). 2004. PMID: 15152804 Free article.

2

Antitumor activity of ER-37328, a novel carbazole topoisomerase II inhibitor.

Nakamura K, Sugumi H, Yamaguchi A, Uenaka T, Kotake Y, Okada T, Kamata J, Niijima J, Nagasu T, Koyanagi N, Yoshino H, Kitoh K, Yoshimatsu K. Nakamura K, et al. Among authors: uenaka t. Mol Cancer Ther. 2002 Jan;1(3):169-75. Mol Cancer Ther. 2002. PMID: 12467211

3

A novel carbazole topoisomerase II poison, ER-37328: potent tumoricidal activity against human solid tumors in vitro and in vivo.

Nakamura K, Uenaka T, Nagasu T, Sugumi H, Yamaguchi A, Kotake Y, Okada T, Kamata J, Niijima J, Taniguchi T, Koyanagi N, Yoshino H, Kitoh K, Yoshimatsu K. Nakamura K, et al. Among authors: uenaka t. Cancer Sci. 2003 Jan;94(1):119-24. doi: 10.1111/j.1349-7006.2003.tb01362.x. Cancer Sci. 2003. PMID: 12708485 Free PMC article.

4

Synthesis and evaluation of novel pyrimido-acridone, -phenoxadine, and -carbazole as topoisomerase II inhibitors.

Kamata J, Okada T, Kotake Y, Niijima J, Nakamura K, Uenaka T, Yamaguchi A, Tsukahara K, Nagasu T, Koyanagi N, Kitoh K, Yoshimatsu K, Yoshino H, Sugumi H. Kamata J, et al. Among authors: uenaka t. Chem Pharm Bull (Tokyo). 2004 Sep;52(9):1071-81. doi: 10.1248/cpb.52.1071. Chem Pharm Bull (Tokyo). 2004. PMID: 15340192 Free article.

5

E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition.

Matsui J, Yamamoto Y, Funahashi Y, Tsuruoka A, Watanabe T, Wakabayashi T, Uenaka T, Asada M. Matsui J, et al. Among authors: uenaka t. Int J Cancer. 2008 Feb 1;122(3):664-71. doi: 10.1002/ijc.23131. Int J Cancer. 2008. PMID: 17943726

6

Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase.

Matsui J, Funahashi Y, Uenaka T, Watanabe T, Tsuruoka A, Asada M. Matsui J, et al. Among authors: uenaka t. Clin Cancer Res. 2008 Sep 1;14(17):5459-65. doi: 10.1158/1078-0432.CCR-07-5270. Clin Cancer Res. 2008. PMID: 18765537

7

Enhanced anti-angiogenic effect of E7820 in combination with erlotinib in epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small-cell lung cancer xenograft models.

Ito K, Semba T, Uenaka T, Wakabayashi T, Asada M, Funahashi Y. Ito K, et al. Among authors: uenaka t. Cancer Sci. 2014 Aug;105(8):1023-31. doi: 10.1111/cas.12450. Cancer Sci. 2014. PMID: 24841832 Free PMC article.

8

Apratoxin A Shows Novel Pancreas-Targeting Activity through the Binding of Sec 61.

Huang KC, Chen Z, Jiang Y, Akare S, Kolber-Simonds D, Condon K, Agoulnik S, Tendyke K, Shen Y, Wu KM, Mathieu S, Choi HW, Zhu X, Shimizu H, Kotake Y, Gerwick WH, Uenaka T, Woodall-Jappe M, Nomoto K. Huang KC, et al. Among authors: uenaka t. Mol Cancer Ther. 2016 Jun;15(6):1208-16. doi: 10.1158/1535-7163.MCT-15-0648. Epub 2016 Mar 29. Mol Cancer Ther. 2016. PMID: 27196783

9

E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models.

Watanabe Miyano S, Yamamoto Y, Kodama K, Miyajima Y, Mikamoto M, Nakagawa T, Kuramochi H, Funasaka S, Nagao S, Sugi NH, Okamoto K, Minoshima Y, Nakatani Y, Karoji Y, Ohashi I, Yamane Y, Okada T, Matsushima T, Matsui J, Iwata M, Uenaka T, Tsuruoka A. Watanabe Miyano S, et al. Among authors: uenaka t. Mol Cancer Ther. 2016 Nov;15(11):2630-2639. doi: 10.1158/1535-7163.MCT-16-0261. Epub 2016 Aug 17. Mol Cancer Ther. 2016. PMID: 27535969

10

E7386, a Selective Inhibitor of the Interaction between β-Catenin and CBP, Exerts Antitumor Activity in Tumor Models with Activated Canonical Wnt Signaling.

Yamada K, Hori Y, Inoue S, Yamamoto Y, Iso K, Kamiyama H, Yamaguchi A, Kimura T, Uesugi M, Ito J, Matsuki M, Nakamoto K, Harada H, Yoneda N, Takemura A, Kushida I, Wakayama N, Kubara K, Kato Y, Semba T, Yokoi A, Matsukura M, Odagami T, Iwata M, Tsuruoka A, Uenaka T, Matsui J, Matsushima T, Nomoto K, Kouji H, Owa T, Funahashi Y, Ozawa Y. Yamada K, et al. Among authors: uenaka t. Cancer Res. 2021 Feb 15;81(4):1052-1062. doi: 10.1158/0008-5472.CAN-20-0782. Epub 2021 Jan 6. Cancer Res. 2021. PMID: 33408116

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

42 results

Search Page

Filters